Roche’s Glofitamab Receives NICE Recommendation for the Treatment of Diffuse Large B-Cell Lymphoma
Shots:
- NICE has issued the final guidance recommending glofitamab as a new treatment option for adults with r/r diffuse large B cell lymphoma after ≥2 systemic treatments
- The P-I/II study (NP30179) showed that 35.2% of patients achieved a complete response while the clinical trial evidence showed that patients treated with glofitamab reached complete remission with no signs or symptoms of cancer. It also suggests that glofitamab can provide patients with longer survival time and have longer before the disease progresses
- Glofitamab received conditional marketing authorization from the EMA in July 2023 for treating adult patients with DLBCL after ≥2 lines of systemic therapy
Ref: NICE | Image: Roche
Related News:- Roche’s Columvi (glofitamab) Receives EC’s Conditional Marketing Authorization for Relapsed or Refractory Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
